All In Biotech

Drug Trial Radar · NCT05957367

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

94

Planned (sponsor's estimate)

Start

Sep 28, 2023

Primary completion

Mar 2027

Study completion Mar 2029

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.

Conditions

  • GIST

Interventions

  • InlexisertibDrug

    Oral Tablet Formulation

  • RipretinibDrug

    Oral Tablet Formulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (Escalation Phase)Time frame: Approximately 24 months
  2. Recommended Phase 2 Doses (RP2D) (Escalation Phase)Time frame: Approximately 18 months
  3. Objective response rate (ORR) (Expansion Phase)Time frame: Approximately 24 months

Locations

28 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Southern California - Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Department of Medicine-Hematology/Oncology

    Los Angeles, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • University of Massachusetts Worcester

    Worcester, Massachusetts

  • START Midwest

    Grand Rapids, Michigan

  • Washington University School of Medicine - Siteman Cancer Center

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center - Main Campus

    New York, New York

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Virginia Cancer Specialist, PC

    Fairfax, Virginia

  • Aarhus University Hospital

    Aarhus, Denmark

  • Centre Oscar Lambret

    Lille, France

  • Institut Curie, Service d'Oncologie Médicale

    Paris, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Universitatsklinikum Franfurt

    Frankfurt, Germany

  • Universitätsklinikum Eppendorf

    Hamburg, Germany

  • AOU Careggi - Padiglione 16 - Piano Terra - Ambulatori Oncologici - Ufficio Trial

    Florence, Italy

  • IRCCS Azienda Ospedaliera Metropolitana

    Genova, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Antonie Van Leeuwenhoek Hospital

    Amsterdam, Netherlands

  • Radboudumc

    Nijmegen, Netherlands

  • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E.

    Porto, Portugal

  • ICO Hospitalet

    Barcelona, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario Clinico San Carlos

    Madrid, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, Spain

  • Inselspital Universitätsklinikum Bern

    Bern, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.